Development of a Novel Clinical Diagnostic Assay for Peripheral T-cell Lymphoma (PTCL)

开发外周 T 细胞淋巴瘤 (PTCL) 的新型临床诊断方法

基本信息

  • 批准号:
    9555564
  • 负责人:
  • 金额:
    $ 29.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-04-01 至 2020-03-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract Peripheral T-cell lymphoma (PTCL) is a heterogeneous cancer that constitutes up to 20% of all non-Hodgkin lymphoma (NHL). The World Health Organization classification recognizes a number of distinct subtypes of PTCL but the diagnosis of these different subtypes is challenging even for expert hematopathologists. Furthermore, 30-50% of PTCL cases are not classifiable into any specific subtype at all using current diagnostic methods. Patients with PTCL generally have a poor prognosis with current standard-of-care therapy, and no improvement in the outcome of PTCL patients has been achieved in the last two decades. However, novel therapies targeted to specific PTCL subtypes have recently begun testing, some with spectacular results. Accurate diagnosis of PTCL and its subtypes has therefore become essential to ensure selection of the most appropriate and effective treatment for each individual patient. This project will leverage seminal work performed by academic investigators associated with the Lymphoma/Leukemia Molecular Profiling Project (LLMPP), in which robust molecular gene expression (GE) signatures have been identified that are unique to each major subtype of PTCL. The project will build upon this work, utilizing it as the basis for the creation of a commercial assay for routine clinical application to improve the diagnosis, treatment, and outcomes of PTCL patients. HealthChart LLC, a recently founded molecular diagnostics firm focused on the development of novel diagnostic assays for niche indications in cancer and other diseases, has licensed the intellectual property and patent portfolio associated with the academic work and is the small business partner in these proposed studies. The overarching goal of this Phase 1 STTR proposal is to transition the “academic” PTCL diagnostic and prognostic GE signatures originally developed using fresh frozen specimens analyzed with expression microarrays to an optimized, locked-down signature applicable to formalin-fixed paraffin-embedded (FFPE) specimens analyzed on the NanoString nCounter platform. The two Aims of this proposal – Aim 1. Identify a reduced set of transcripts and create a novel model able to replicate the existing “academic” diagnostic and prognostic PTCL signature; Aim 2. Confirm the applicability of the refined diagnostic and prognostic PTCL gene signature sets on the nCounter platform (NanoString) for the analysis of FFPE specimens – will create an optimized and locked-down PTCL signature, establish performance specifications for inter-lab reproducibility, and validate the signature to a rigorous set of target metrics. These studies will enable application of the assay as a CLIA lab offering at the end of Phase 1, while positioning the PTCL assay for transition to Phase 2 development as an in vitro diagnostic (IVD) kit and possibly a companion diagnostic (CDx) for novel and/or existing PTCL therapies.
项目摘要/摘要 外周T细胞淋巴瘤(PTCL)是一种异质性肿瘤,占所有非霍奇金淋巴瘤的20% 淋巴瘤(NHL)。世界卫生组织的分类承认了许多不同的亚型 但这些不同亚型的诊断即使对专业的血液病理学家来说也是具有挑战性的。 此外,30%-50%的PTCL病例根本不能归类为任何特定的亚型 诊断方法。根据目前的护理标准,PTCL患者的预后一般较差。 在过去的二十年里,PTCL患者的预后没有任何改善。 然而,针对特定PTCL亚型的新疗法最近已开始测试,其中一些 令人惊叹的结果。因此,对PTCL及其亚型的准确诊断对于确保 为每个患者选择最合适和最有效的治疗方法。这个项目将 利用与淋巴瘤/白血病相关的学术研究人员所做的开创性工作 分子图谱计划(LLMPP),在该计划中,强大的分子基因表达(GE)签名已经 确定了PTCL每个主要亚型所特有的基因。该项目将在这项工作的基础上,利用它作为 创建用于常规临床应用的商业分析以改进诊断的基础, PTCL患者的治疗和转归。HealthChart LLC,一家最近成立的分子诊断公司 重点开发癌症和其他疾病的利基适应症的新诊断分析方法, 已授权与学术工作相关的知识产权和专利组合,并是 这些拟议研究中的小企业合作伙伴。此第一阶段STTR提案的总体目标是 是将最初使用以下工具开发的“学术”PTCL诊断和预后GE信号 利用表达微阵列分析新鲜冷冻样品以获得优化、锁定的签名 适用于纳米串计数器分析的福尔马林固定石蜡包埋(FFPE)标本 站台。这项提议的两个目标-目标1.确定一组减少的成绩单并创作一部小说 能够复制现有的“学术”诊断和预后PTCL信号的模型;目标2。 确认改进的诊断和预后PTCL基因签名集在 用于分析FFPE样本的计数器平台(NanoString)-将创建一个优化的和 锁定PTCL签名,建立实验室间可重复性的性能规范,并验证 一套严格的目标指标的签名。这些研究将使该检测作为CLIA的应用成为可能 在第一阶段结束时提供实验室服务,同时将过渡到第二阶段开发的PTCL分析定位为 新的和/或现有的PTCL的体外诊断(IVD)试剂盒和可能的伴随诊断(CDX) 治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Wing C. Chan其他文献

Heterogeneity of large granular lymphocyte proliferations: delineation of two major subtypes.
大颗粒淋巴细胞增殖的异质性:两种主要亚型的划分。
  • DOI:
  • 发表时间:
    1986
  • 期刊:
  • 影响因子:
    20.3
  • 作者:
    Wing C. Chan;A. Mawle;Irene J. Check;Russell K. Brynes;Elliott F. Winton
  • 通讯作者:
    Elliott F. Winton
Mechanistic Elucidation of the Tumor-Promoting Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in B-Cell Receptor Signaling in Mantle Cell Lymphoma
  • DOI:
    10.1182/blood-2023-175064
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Serene Xavier;Vivian Nguyen;Vishal Khairnar;An Phan;Lu Yang;Michael Nelson;Elizabeth Tseng;Aimin Li;Joo Y Song;Dennis D. Weisenburger;Wing C. Chan;Markus Müschen;Vu N. Ngo
  • 通讯作者:
    Vu N. Ngo
Lymphomas of follicles. Mantle cell and follicle center cell lymphomas.
滤泡淋巴瘤。
Large granular lymphocyte proliferation: an analysis of T-cell receptor gene arrangement and expression and the effect of in vitro culture with inducing agents.
大颗粒淋巴细胞增殖:T细胞受体基因排列和表达以及诱导剂体外培养效果的分析。
  • DOI:
  • 发表时间:
    1988
  • 期刊:
  • 影响因子:
    20.3
  • 作者:
    Wing C. Chan;Carol DahI;Thomas A. Waldmann;Susan Link;Alison Mawle;Janet K. A. Nicholson;Fritz H. Bach;K. Bongiovanni;Peter A. McCue;Elliott F. Winton
  • 通讯作者:
    Elliott F. Winton
Peripheral T cell lymphomas: from the bench to the clinic
外周 T 细胞淋巴瘤:从实验室到临床
  • DOI:
    10.1038/s41568-020-0247-0
  • 发表时间:
    2020-04-06
  • 期刊:
  • 影响因子:
    66.800
  • 作者:
    Danilo Fiore;Luca Vincenzo Cappelli;Alessandro Broccoli;Pier Luigi Zinzani;Wing C. Chan;Giorgio Inghirami
  • 通讯作者:
    Giorgio Inghirami

Wing C. Chan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Wing C. Chan', 18)}}的其他基金

Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures
生物分析物的分析前变量影响 PTCL 诊断和预后遗传特征的准确性
  • 批准号:
    10300391
  • 财政年份:
    2021
  • 资助金额:
    $ 29.94万
  • 项目类别:
Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures
生物分析物的分析前变量影响 PTCL 诊断和预后遗传特征的准确性
  • 批准号:
    10491082
  • 财政年份:
    2021
  • 资助金额:
    $ 29.94万
  • 项目类别:
Cooperative role of TET2 and IDH2 mutations in angioimmunoblastic T-cell lymphomagenesis
TET2 和 IDH2 突变在血管免疫母细胞 T 细胞淋巴瘤发生中的协同作用
  • 批准号:
    10672370
  • 财政年份:
    2021
  • 资助金额:
    $ 29.94万
  • 项目类别:
Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures
生物分析物的分析前变量影响 PTCL 诊断和预后遗传特征的准确性
  • 批准号:
    10684317
  • 财政年份:
    2021
  • 资助金额:
    $ 29.94万
  • 项目类别:
Cooperative role of TET2 and IDH2 mutations in angioimmunoblastic T-cell lymphomagenesis
TET2 和 IDH2 突变在血管免疫母细胞 T 细胞淋巴瘤发生中的协同作用
  • 批准号:
    10299140
  • 财政年份:
    2021
  • 资助金额:
    $ 29.94万
  • 项目类别:
Cooperative role of TET2 and IDH2 mutations in angioimmunoblastic T-cell lymphomagenesis
TET2 和 IDH2 突变在血管免疫母细胞 T 细胞淋巴瘤发生中的协同作用
  • 批准号:
    10453656
  • 财政年份:
    2021
  • 资助金额:
    $ 29.94万
  • 项目类别:
Molecular diagnostic and prognostic signatures for PTCL
PTCL 的分子诊断和预后特征
  • 批准号:
    10017897
  • 财政年份:
    2017
  • 资助金额:
    $ 29.94万
  • 项目类别:
Molecular diagnostic and prognostic signatures for PTCL
PTCL 的分子诊断和预后特征
  • 批准号:
    10226182
  • 财政年份:
    2017
  • 资助金额:
    $ 29.94万
  • 项目类别:
Molecular Signatures to Improve Diagnosis and Outcome Pr
改善诊断和结果的分子特征
  • 批准号:
    7913564
  • 财政年份:
    2009
  • 资助金额:
    $ 29.94万
  • 项目类别:
Gene expression profiling and pathway targeted therapy in peripheral T-cell
外周T细胞的基因表达谱和通路靶向治疗
  • 批准号:
    7715220
  • 财政年份:
    2009
  • 资助金额:
    $ 29.94万
  • 项目类别:

相似海外基金

DMS-EPSRC: Asymptotic Analysis of Online Training Algorithms in Machine Learning: Recurrent, Graphical, and Deep Neural Networks
DMS-EPSRC:机器学习中在线训练算法的渐近分析:循环、图形和深度神经网络
  • 批准号:
    EP/Y029089/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.94万
  • 项目类别:
    Research Grant
CAREER: Blessing of Nonconvexity in Machine Learning - Landscape Analysis and Efficient Algorithms
职业:机器学习中非凸性的祝福 - 景观分析和高效算法
  • 批准号:
    2337776
  • 财政年份:
    2024
  • 资助金额:
    $ 29.94万
  • 项目类别:
    Continuing Grant
CAREER: From Dynamic Algorithms to Fast Optimization and Back
职业:从动态算法到快速优化并返回
  • 批准号:
    2338816
  • 财政年份:
    2024
  • 资助金额:
    $ 29.94万
  • 项目类别:
    Continuing Grant
CAREER: Structured Minimax Optimization: Theory, Algorithms, and Applications in Robust Learning
职业:结构化极小极大优化:稳健学习中的理论、算法和应用
  • 批准号:
    2338846
  • 财政年份:
    2024
  • 资助金额:
    $ 29.94万
  • 项目类别:
    Continuing Grant
CRII: SaTC: Reliable Hardware Architectures Against Side-Channel Attacks for Post-Quantum Cryptographic Algorithms
CRII:SaTC:针对后量子密码算法的侧通道攻击的可靠硬件架构
  • 批准号:
    2348261
  • 财政年份:
    2024
  • 资助金额:
    $ 29.94万
  • 项目类别:
    Standard Grant
CRII: AF: The Impact of Knowledge on the Performance of Distributed Algorithms
CRII:AF:知识对分布式算法性能的影响
  • 批准号:
    2348346
  • 财政年份:
    2024
  • 资助金额:
    $ 29.94万
  • 项目类别:
    Standard Grant
CRII: CSR: From Bloom Filters to Noise Reduction Streaming Algorithms
CRII:CSR:从布隆过滤器到降噪流算法
  • 批准号:
    2348457
  • 财政年份:
    2024
  • 资助金额:
    $ 29.94万
  • 项目类别:
    Standard Grant
EAGER: Search-Accelerated Markov Chain Monte Carlo Algorithms for Bayesian Neural Networks and Trillion-Dimensional Problems
EAGER:贝叶斯神经网络和万亿维问题的搜索加速马尔可夫链蒙特卡罗算法
  • 批准号:
    2404989
  • 财政年份:
    2024
  • 资助金额:
    $ 29.94万
  • 项目类别:
    Standard Grant
CAREER: Efficient Algorithms for Modern Computer Architecture
职业:现代计算机架构的高效算法
  • 批准号:
    2339310
  • 财政年份:
    2024
  • 资助金额:
    $ 29.94万
  • 项目类别:
    Continuing Grant
CAREER: Improving Real-world Performance of AI Biosignal Algorithms
职业:提高人工智能生物信号算法的实际性能
  • 批准号:
    2339669
  • 财政年份:
    2024
  • 资助金额:
    $ 29.94万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了